Compare · DXCM vs STSS
DXCM vs STSS
Side-by-side comparison of DexCom Inc. (DXCM) and Sharps Technology Inc. (STSS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and STSS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.85B, about 370.5x STSS ($77.9M).
- Over the past year, DXCM is down 10.0% and STSS is down 69.1% - DXCM leads by 59.1 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 5 for STSS).
- DXCM has more recent analyst coverage (25 ratings vs 0 for STSS).
- Company
- DexCom Inc.
- Sharps Technology Inc.
- Price
- $74.78-4.36%
- $1.84+1.10%
- Market cap
- $28.85B
- $77.9M
- 1M return
- +26.00%
- +2.22%
- 1Y return
- -10.02%
- -69.08%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2022
- News (4w)
- 26
- 5
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Sharps Technology Inc.
Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest STSS
- SEC Form 3 filed by new insider Levine Arthur
- Sharps Technology Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- Sharps Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
- SkyAI Appoints Veteran Finance Executive Arthur Levine as Chief Financial Officer
- Sharps Technology Becomes SkyAI, Inc. with New Ticker Symbol "SKYA"; Establishing Category-defining Agentic Finance Platform Serving Global South
- Amendment: SEC Form SCHEDULE 13G/A filed by Sharps Technology Inc.
- Sharps Technology Reports Continued Growth in Q1 2026 Highlighting Strengthened Balance Sheet and Strong Treasury Execution
- Sharps Technology Adopts Limited Duration Stockholder Rights Plan
- SEC Form 10-Q filed by Sharps Technology Inc.
- Sharps Technology Reports 2025 Year-End Results and Highlights Continued Execution of Solana Treasury Strategy